LMWH to Prevent Preeclampsia and Fetal Growth Restriction
Status:
Terminated
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The objective of this trial will be to determine whether prophylactic low-molecular weight
heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A
prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe
fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal
growth restriction, or both.